Product Dossier
QDENGA
Product Dossier for QDENGA (dengue virus serotype 1, Takeda Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes, AusPAR — compiled by arcimedes.
- Sponsor: Takeda Pharmaceuticals
- Active ingredient: dengue virus serotype 1
- Therapeutic area: Infectious Disease
- Same area: FETROJA
- Same area: ROXAR
What it is
QDENGA is a dengue tetravalent vaccine (live, attenuated) containing dengue virus serotypes 1, 2, 3, and 4.
Regulatory history
QDENGA was first listed on the ARTG on 8 April 2026. Two variants are registered: a powder (vial) and solvent (PFS) formulation, and a powder (vial) and solvent (vial) formulation.